comparability protocols nancy sager associate director, qis-chemistry fda/cder/ops
DESCRIPTION
Comparability Protocols A well-defined, detailed written plan for assessing the effect of specific postapproval chemistry, manufacturing, and controls (CMC) changes on the identity, strength, quality, purity, and potency of a specific drug product A plan for anticipated future CMC changes The protocol can be submitted in an original application or a prior approval supplement (postapproval)TRANSCRIPT
![Page 1: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/1.jpg)
Comparability Protocols
Nancy SagerAssociate Director, QIS-Chemistry
FDA/CDER/OPS
![Page 2: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/2.jpg)
Overview
• What is a comparability protocol?
• Why has FDA issued a guidance on comparability protocols?
• What are the benefits of using comparability protocols?
• Why are we making the ACPS aware of this guidance?
• What are the principles of comparability protocols? (Stephen Moore)
![Page 3: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/3.jpg)
Comparability Protocols
• A well-defined, detailed written plan for assessing the effect of specific postapproval chemistry, manufacturing, and controls (CMC) changes on the identity, strength, quality, purity, and potency of a specific drug product
• A plan for anticipated future CMC changes
• The protocol can be submitted in an original application or a prior approval supplement (postapproval)
![Page 4: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/4.jpg)
Why Develop a Guidance
• Concept for comparability protocols first introduced for biotechnology products (1997)
• Industry requests to extend concept to all drugs and for additional guidance
![Page 5: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/5.jpg)
Why Develop a Guidance
• Provide recommendations to applicants on developing a protocol to assess the effect of postapproval changes based on specific knowledge of a product and process (e.g., development data, manufacturing experience)
![Page 6: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/6.jpg)
Why Develop a Guidance• Consistent and complimentary to FDA initiatives on
risk management
– A well-planned protocol provides sufficient information for FDA to determine whether the potential for an adverse effect on the product can be adequately evaluated and can lower the risk for implementing the change without FDA’s prior approval
– Augments the Scale-up and Postapproval Changes (SUPAC) and Changes to an Approved NDA or ANDA guidances
![Page 7: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/7.jpg)
Why Develop a Guidance
• Consistent and complimentary to FDA initiatives on pharmaceutical cGMPs for the 21st century
– Promote continual process and product improvement and innovation by facilitating CMC changes
![Page 8: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/8.jpg)
Benefits
• FDA can designate, where appropriate, a reduced reporting category for future reporting of CMC changes covered by the approved protocol
– Prior approval supplement– Changes-being-effected in 30 Days supplement (CBE-30)– Changes-being-effected supplement (CBE-0)– Annual report
![Page 9: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/9.jpg)
Benefits
• An FDA request for additional information to support a change is less likely when the change is covered under an approved protocol
• Could allow an applicant to implement CMC changes and place product in distribution sooner than without the use of a comparability protocol
![Page 10: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/10.jpg)
Benefits
• Allows companies to “design their own SUPAC” based on their knowledge of and experience with a product
• Provides an opportunity for a reduced reporting category for CMC changes when the dosage form is not covered by a SUPAC type document
![Page 11: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/11.jpg)
ACPS’s Role
At this time, CDER has little experience with comparability protocols. The ACPS may be asked to provide advice on:
• Issues raised by public comments on the guidance
• Specific proposals for comparability protocols
![Page 12: Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS](https://reader036.vdocument.in/reader036/viewer/2022082412/5a4d1b637f8b9ab0599aeba8/html5/thumbnails/12.jpg)
Guidance
• Available at: http://www.fda.gov/cder/guidance/5427dft.pdf
• Draft guidance published: February 25, 2003
• Comment period closes: June 25, 2003